Atezolizumab

4:06
Strategies to reduce drug costs
Mark Ratain
3:59
Interventional pharmoeconomics to reduce the cost of therapy
Mark Ratain
3:45
Molecular target therapy in pancreatic and liver cancer
Hani Babiker
1:50
IMpower133: atezolizumab, carboplatin plus etoposide for SCLC
Martin Reck
4:20
IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
Thomas Powles
3:19
PD1 & PDL1 inhibitors for mUC, where are we?
Petros Grivas
2:57
Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma
Enrique Grande
7:21
IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma
Enrique Grande
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
3:58
Atezolizumab and bevacizumab for upfront unresectable HCC
Michael Lee
1:02
Non-clear cell sarcamatoid kidney cancer treatment updates
Rana McKay
4:02
Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancer
Rana McKay
1:00
IMpassion130: Implications
Peter Schmid
2:30
IMpassion130: immunotherapy for TNBC
Peter Schmid
1:47
TNBC: work to be done
Peter Schmid
0:47
Atezolizumab for TNBC
Erika Hamilton
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals